Dr. O’Malley on the Efficacy of Pembrolizumab in Advanced Ovarian Cancer


In Partnership With:

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

David M. O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University (OSU)College of Medicine, director of the Division of Gynecologic Oncology, and co-director of the Gynecologic Oncology Phase I Program at The OSU Comprehensive Cancer Center–James, discusses the efficacy of pembrolizumab (Keytruda) in patients with advanced ovarian cancer.

PD-1 inhibitors have demonstrated modest activity when administered as single agents, O’Malley says. In the phase 2 KEYNOTE-100 trial (NCT02674061), pembrolizumab was examined in 2 cohorts of patients with advanced ovarian cancer, according to O’Malley. Cohort A enrolled patients who had received 1 to 3 prior therapies, and cohort B included those who had received 4 to 6 prior therapies, O’Malley explains. Results showed that pembrolizumab was consistent with other single-agent checkpoint inhibitors, with an overall response rate of approximately 10%, O’Malley adds. 

When looking at sub-populations, such as those examined on this study, data suggest that response rates with this agent appear to increase as the PD-L1 combined positive score increases, O’Malley says. As such, there may be a biomarker that can help predict response to immunotherapy in this patient population, concludes O’Malley.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS